Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
Climb Bio, Inc. (CLYM)
Company Research
Source: GlobeNewswire
First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory clearance for SLE IND in China First patients dosed in CLYM116 Phase 1 healthy volunteer study Anticipating a data-rich 2026, with initial readouts from all ongoing budoprutug and CLYM116 studies Strong financial position with cash runway expected into 2028 WELLESLEY HILLS, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced progress updates for its budoprutug and CLYM116 programs. The Company also highlighted its strategic priorities and key anticipated milestones for 2026 and refreshed its financial guidance. “Reflecting on 2025, we set out with ambitious goals, and I am proud of the substantial progress made across our clinic
Show less
Read more
Impact Snapshot
Event Time:
CLYM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLYM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLYM alerts
High impacting Climb Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CLYM
News
- Climb Bio (CLYM) had its price target raised by Robert W. Baird from $9.00 to $12.00. They now have an "outperform" rating on the stock.MarketBeat
- Climb Bio (CLYM) is now covered by Wedbush. They set an "outperform" rating and a $12.00 price target on the stock.MarketBeat
- Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates GlobeNewswire
- Climb Bio (NASDAQ:CLYM) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.MarketBeat
CLYM
Earnings
- 3/25/25 - Beat
CLYM
Sec Filings
- 3/5/26 - Form S-8
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- CLYM's page on the SEC website